| Primary |
| B-cell Lymphoma |
54.5% |
| Antiviral Prophylaxis |
9.1% |
| Cystitis Haemorrhagic |
9.1% |
| Gastrooesophageal Reflux Disease |
9.1% |
| Hyperlipidaemia |
9.1% |
| Ischaemic Heart Disease Prophylaxis |
9.1% |
|
|
| Secondary |
| B-cell Lymphoma |
22.0% |
| Product Used For Unknown Indication |
15.2% |
| Diffuse Large B-cell Lymphoma |
9.1% |
| Non-hodgkin's Lymphoma |
7.8% |
| Lymphoma |
6.4% |
| Drug Use For Unknown Indication |
5.7% |
| T-cell Lymphoma |
5.4% |
| Mantle Cell Lymphoma |
4.9% |
| Prophylaxis |
4.8% |
| Sarcoma |
2.8% |
| Plasma Cell Myeloma |
2.4% |
| Sarcoma Metastatic |
2.0% |
| Breast Cancer |
1.8% |
| Hypertension |
1.8% |
| Nodular (Follicular) Lymphoma |
1.8% |
| Acute Lymphocytic Leukaemia |
1.7% |
| Chemotherapy |
1.3% |
| Small Cell Lung Cancer |
1.2% |
| Pain |
1.1% |
| Burkitt's Lymphoma |
1.0% |
|
| Thrombocytopenia |
10.7% |
| Adenocarcinoma |
8.0% |
| Herpes Zoster |
8.0% |
| Myelodysplastic Syndrome |
6.7% |
| Septic Shock |
6.7% |
| Febrile Bone Marrow Aplasia |
5.3% |
| Neuropathy Peripheral |
5.3% |
| Vomiting |
5.3% |
| White Blood Cell Count Decreased |
5.3% |
| Gamma-glutamyltransferase Increased |
4.0% |
| General Physical Health Deterioration |
4.0% |
| Mucosal Inflammation |
4.0% |
| Pneumothorax |
4.0% |
| Pyrexia |
4.0% |
| Sepsis |
4.0% |
| Weight Decreased |
4.0% |
| Agranulocytosis |
2.7% |
| Bone Marrow Failure |
2.7% |
| Device Related Infection |
2.7% |
| Febrile Neutropenia |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.9% |
| Non-hodgkin's Lymphoma |
18.6% |
| Acute Lymphocytic Leukaemia |
8.0% |
| Chemotherapy |
5.1% |
| Hodgkin's Disease |
5.1% |
| Multiple Myeloma |
5.1% |
| Plasma Cell Myeloma |
5.1% |
| Diffuse Large B-cell Lymphoma |
4.6% |
| Plasma Cell Leukaemia |
3.8% |
| B-cell Lymphoma Stage Iv |
2.1% |
| Chronic Lymphocytic Leukaemia |
2.1% |
| Diffuse Large B-cell Lymphoma Stage Iv |
2.1% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
2.1% |
| T-cell Lymphoma |
2.1% |
| Transitional Cell Carcinoma |
2.1% |
| Hiv Infection |
1.7% |
| Leukaemia Plasmacytic |
1.7% |
| Antibiotic Prophylaxis |
1.3% |
| B-cell Lymphoma Stage Ii |
1.3% |
| Drug Use For Unknown Indication |
1.3% |
|
| Septic Shock |
13.3% |
| Visual Impairment |
10.0% |
| Death |
6.7% |
| Disease Progression |
6.7% |
| Pulmonary Fibrosis |
6.7% |
| Respiratory Distress |
6.7% |
| Thrombocytopenia |
6.7% |
| Agranulocytosis |
3.3% |
| Bone Marrow Failure |
3.3% |
| Cholestasis |
3.3% |
| Coma |
3.3% |
| Diffuse Large B-cell Lymphoma Recurrent |
3.3% |
| Drug Ineffective |
3.3% |
| Drug Interaction |
3.3% |
| Encephalopathy |
3.3% |
| Febrile Bone Marrow Aplasia |
3.3% |
| General Physical Health Deterioration |
3.3% |
| Nervous System Disorder |
3.3% |
| Non-hodgkin's Lymphoma |
3.3% |
| Obliterative Bronchiolitis |
3.3% |
|
